natgillin/translations-raw huggingface dataset:
Navodila za pripravo zmanjšanih odmerkov zdravila Zoledronska kislina Actavis Izvlecite ustrezno količino potrebnega koncentrata:
Instructions for preparing reduced doses of Zoledronic acid Actavis Withdraw an appropriate volume of the concentrate needed, as follows:
Navodila za pripravo/ravnanje z zdravilom INOmax
Instructions for use/handling INOmax
Navodila za redčenje
Instructions for dilution
Navodila za redčenje, shranjevanje in odstranjevanje zdravila Topotekan Teva Slošni previdnostni ukrepi
Instructions on how to dilute, store and dispose of Topotecan Teva General precautions
Navodila za uporabo, ravnanje z zdravilom in odstranjevanje
Instructions for use, handling and disposal
Navodila za zdravstveno osebje
Healthcare professional educational pack
Navodilo je bilo nazadnje revidirano dne
This leaflet was last revised in Other sources of information
Navodilo je bilo nazadnje revidirano dne mesec LLLL
This leaflet was last revised in month YYYY.
Navodilo je bilo nazadnje revidirano dne MM/LLLL.
This leaflet was last revised in MM/YYYY.
Navodilo je bilo nazadnje revidirano dne MM/YYYY.
This leaflet was last revised in MM/YYYY.
Navodilo je bilo nazadnje revidirano dne {mesec LLLL}.
This leaflet was last revised in {month YYYY}.
Navodilo je bilo nazadnje revidirano dne {MM/LLLL}.
This leaflet was last revised in month YYYY.
Navodilo je bilo nazadnje revidirano dne {MM/LLLL}.
This leaflet was last revised in {MM/YYYY}.
Navodilo je bilo nazadnje revidirano dne {MM/YYYY}
The leaflet was last revised in {MM/YYYY}.
Navodilo je bilo odobreno
This leaflet was last approved in
Navodilo shranite.
Keep this leaflet.
Navodilo vsebuje
In this leaflet:
Navodilo vsebuje
What is in this leaflet
Navodilo vsebuje:
In this leaflet:
Navodilo za injiciranje zdravila
Instructions for administration
Navodilo za redčenje
Instructions for dilution
NAVODILO ZA UPORABO
PACKAGE INSERT
NAVODILO ZA UPORABO
PACKAGE LEAFLET
NAVODILO ZA UPORABO
PACKAGE LEAFLET FOR:
Navodilo za uporabo
Package leaflet: Information for the patient
Navodilo za uporabo
Package leaflet: Information for the user
NAVODILO ZA UPORABO ZA BRIZGE S PERORALNIM GELOM 3 %
PACKAGE INSERT FOR INCLUSION WITH THE 3% ORAL GEL SYRINGE PACKAGES
NAVODILO ZA UPORABO ZA BRIZGE S PERORALNIM GELOM 7,5 %
PACKAGE INSERT FOR INCLUSION WITH THE 7.5 % ORAL GEL SYRINGE PACKAGES
Navodilo za uporabo,
Package leaflet
NAVODILO ZA UPORABO‌‌
PACKAGE LEAFLET: INFORMATION FOR THE USER‌‌
navzea
nausea
Navštivte www.alli.cz
Visit <www.xxx.xxx>
NAXCEL 100 mg/ml инжекционна суспензия за прасета
NAXCEL 100 mg/ml suspension for injection for pigs
NAXCEL 100 mg/ml инжекционна суспензия за прасета Ceftiofur
NAXCEL 100 mg/ml suspension for injection for pigs Ceftiofur
NAXCEL 100mg/ml инжекционна суспензия за прасета
NAXCEL 100 mg/ml suspension for injection for pigs
NAXCEL 100mg/ml инжекционна суспензия за прасета Ceftiofur
NAXCEL 100 mg/ml suspension for injection for pigs Ceftiofur
NAXCEL 200mg/ml инжекционна суспензия за говеда
NAXCEL 200 mg/ml suspension for injection for cattle
NAXCEL 200mg/ml инжекционна суспензия за говеда.
NAXCEL 200 mg/ml suspension for injection for cattle
NAXCEL трябва да се прилага само подкожно в основата на ухото, в тъкани, които не се използват за консумация, с цел спазване на карентния срок.
NAXCEL must only be administered at the base of ear location in non-edible tissue in order to comply with the withdrawal period.
Nazofaringitis
Nasopharyngitis
NAČIN IN POTI UPORABE
METHOD AND ROUTE(S) OF ADMINISTRATION
NAČIN IZDAJANJA ZDRAVILA
GENERAL CLASSIFICATION FOR SUPPLY
Načeto zdravilo uporabite v 6-ih mesecih.
Once opened, use within 6 months.
Način dajanja odmerkov je na kratko prikazan v Preglednici 4.
The treatment regimen is summarized in Table 4.
Način uporabe
Method of administration
Način uporabe Intravenska uporaba.
Method of administration Intravenous use.
Način uporabe peroralna uporaba
Method of administration Oral use.
Načrt za obvladovanje tveganj (RMP)
Risk Management Plan (RMP)
Načrt za obvladovanje tveganja (RMP)
Risk Management Plan
Načrt za obvladovanje tveganja (RMP)
Risk Management Plan (RMP)
Načrt za obvladovanje tveganja (RMP)
Risk Management Plan (RMP) Not applicable.
Naštete izsledke je treba upoštevati ob uvajanju zdravljenja s pramipeksolom pri bolnikih s Parkinsonovo boleznijo.
These points should be considered when initiating pramipexole treatment in patients with Parkinson’s disease.
NAб
NAb
NC 27330, Sanford, САЩ
NC 27330, Sanford, USA
NC = F: non-completers = failures (пациенти, незавършили изпитването = неуспех)
NC = F: non-completers = failures
NC = нe е изчислено
NC = not calculated.
NC=F
112
NCI-CTCAE v3 степенa
NCI-CTCAE v3 Gradea
NCKP: ИПЗ3 от ваксиналните серотипове
NCKP: Vaccine-serotype IPD3
NCKP: Клинично доказана пневмония с патологична рентгенография на гръдния кош
NCKP: Clinical pneumonia with abnormal chest X-ray
NCKP: Остро възпаление на средното ухо (ОВСУ)4
NCKP: Acute Otitis Media (AOM)4
nCR n (%)
nCR n(%)
nCR бр. (%)
nCR n (%)
ND
NR
ND Ni dosežen
NA Not Applicable
ND: Неопределен
ND: Not determined
NE (32,1, NE)
NE (32.1, NE)
NE (8,1; NE)
NE (8.1, NE)
NE (8,3; NE)
NE (8.3, NE)
NE = Не може да бъде изчислено. a Медианата се базира на изчислението по Kaplan-Meier.
NE = Not Estimable. a The median is based on Kaplan-Meier estimate.
NE = не е оценимо
NE = not estimable
Ne dajajte tega zdravila otrokom ali mladostnikom, ker ne deluje.
Do not give this medicine to children because it does not work.
Ne dotikajte se aktivacijskih nastavkov ščitnika igle (ki sta označena z zvezdico na Sliki 1), da ne bi prišlo do prezgodnjega prekritja igle s ščitnikom igle.
Do not touch the needle guard activation clips (as indicated by asterisks * in Figure 1) to prevent prematurely covering the needle with the needle guard.
Ne dotikajte se igle in pazite, da se z njo ničesar ne dotaknete.
Do not touch the needle or allow it to touch any surface
Ne drgnite kože na mestu injiciranja.
Do not rub the skin at the injection site.
Ne jemljite zdravila Pravafenix, če ste mlajši od 18 let.
Do not take Pravafenix if you are under 18 years old
Ne mešajte PhotoBarra z drugimi medicinskimi izdelki v isti raztopini.
Do not mix PhotoBarr with other medicinal products in the same solution.
Ne nosite tesnih oblačil.
Avoid tight clothing
Ne poskušajte nadomestiti pozabljenega odmerka.
Do not try to make up for the missed dose.
Ne prenehajte z jemanjem zdravila Pravafenix, dokler se ne posvetujete z zdravnikom.
Do not stop taking Pravafenix without first discussing it with your doctor.
Ne smemo ga dajati psom in mačkam z znano preobčutljivostjo za kinolone.
Do not use in dogs and cats with known quinolone hypersensitivity.
Ne smemo ga dajati psom z znano preobčutljivostjo za kinolone.
Do not use in dogs with known quinolone hypersensitivity.
Ne smemo ga uporabljati pri psih z znano preobčutljivostjo za kinolone.
Do not use in dogs with known quinolone hypersensitivity.
Ne smete ga dajati psom z znano preobčutljivostjo za kinolone.
Do not use in dogs with known quinolone hypersensitivity.
Ne snemajte pokrovčka igle z napolnjene injekcijske brizge, dokler ni to zahtevano v navodilu.
Do not remove the needle cover from the pre-filled syringe until instructed to do so
Ne stresajte.
Do not shake.
Ne stresajte. za subkutano uporabo
Do not shake.
Ne uporabite pri psih, ki so lažji od 3 kg.
Do not use in dogs with a weight of less than 3 kg.
Ne uporabite pri psih, mlajših od 6 tednov starosti.
Do not use in dogs less than 6 weeks of age.
Ne uporabite pri psih, mlajših od 6 tednov.
Do not use in dogs less than 6 weeks of age.
Ne uporabite v primeru preobčutljivosti na zdravilno učinkovino ali na katero koli pomožno snov.
Do not use in case of hypersensitivity to the active substance or to any of the excipients.
Ne uporabljajte butilne gume, poliamida in poliuretana.
Butyl rubber, polyamide, and polyurethane should not be used.
Ne uporabljajte po datumu izteka roka uporabnosti, ki sledi napiseu EXP na ovojnini.
Do not use after the expiry date stated on the label and carton after EXP.
Ne uporabljajte po datumu izteka roka uporabnosti, ki sledi napisu EXP na ovojnini.
Do not use after the expiry date stated on the label and carton after EXP.
Ne uporabljajte pri brejih ali doječih psicah.
Do not use in pregnant or lactating dogs
Ne uporabljajte pri brejih ali doječih psicah.
Do not use in pregnant or lactating dogs.
Ne uporabljajte pri mačkah.
Do not use in cats.
Ne zamrzujte.
Do not freeze.
Ne zaužijte izpuščenega odmerka in ne vzemite dvojnega odmerka, če ste pozabili vzeti prejšnji odmerek.
Do not take the missed dose at all and do not take a double dose to make up for a forgotten dose.
NE  не може да се оцени
NE  not estimable
NE2 (14,6; -)
NE2 (14.6, -)
NE2 (21,6; -)
NE2 (21.6, -)
NE: Не може да се оцени (медианата все още не е достигната; общата медиана на продължителност на  проследяването е 26,3 месеца)
NE: not estimable (median not yet reached; overall median duration of follow-up 26.3 months)
NE=Медиана не е достигната.
NE=Median was not reached.
Neb AAD системата представлява портативна, преносима, небулизираща технологична система с вибрираща мембрана.
The I-Neb AAD System is a portable, hand-held, vibrating mesh technology nebuliser system.
Nebyly prokázány rozdíly ve vylučování orlistatu u dobrovolníků s normální hmotností a obézních.
The disposition of orlistat appeared to be similar between normal weight and obese volunteers.
NECд,
Hypertension
NECд,
NECe (incl.
Nederland
Eesti
Nederland
España
Nederland
France
Nederland
Ireland
Nederland
Italia
Nederland
Lietuva
Nederland
Malta
Nederland
Österreich
Nederland GlaxoSmithKline BV Tel: + 31 (0)30 69 38 100 nlinfo@gsk.com
Nederland GlaxoSmithKline BV Tel: + 31 (0)30 69 38 100 produkt.info@gsk.com nlinfo@gsk.com
Nederland GlaxoSmithKline BV Tel: + 31 (0)30 6938100 nlinfo@gsk.com
Tel: + 31 (0)30 6938100 nlinfo@gsk.com
Nederland medac GmbH
Ne de rland medac GmbH
Nederland Sandoz B.V. Veluwezoom 22
Veluwezoom 22
Nederland/Pays-Bas/Niederlande/Нидерландия/Nizozemsko/ Nederlandene/Holland/Ολλανδία/Nizozemska/The Netherlands/Holland/ Ολλανδία/Nīderlande/Nyderlandai/Pays-Bas/Niederlande/Hollandia/
Nederland/Pays-Bas/Niederlande/Нидерландия/Nizozemsko/ Nederlandene/Holland/Ολλανδία/Nizozemska/The Netherlands/Holland/Ολλανδία/ Nīderlande/Nyderlandai/Pays-Bas/Niederlande/Hollandia/
Nedoporučuje se přijímat denně méně než 1200 kalorií.
Eating fewer than 1200 calories per day is not recommended.
Nedsatt leverfunktion
Hepatic impairment
Nedsatt njurfunktion
Renal impairment
nedávné závažné zranění
a recent serious injury
Need andmed näitavad, et mikafungiini eliminatsioon on peamiselt mitterenaalne.
These data indicate that elimination of micafungin is primarily non-renal.
Need andmed on ebapiisavad, et toetada manustamissoovitusi raske maksakahjustusega patsientidel.
These data are insufficient to support a dosing recommendation in patients with severe hepatic impairment.
Need andmed on ebapiisavad, et toetada manustamissoovitusi raske maksakahjustusega patsientidel.
These data are insufficient to support a dosing recommendation in patients with severe hepatic impairment..
Neerude ja
Renal and urinary disorders
Neerude ja kuseteede häired
Renal and urinary disorders
Neerukahjustusega patsiendid
Patients with renal impairment
Neerukahjustusega patsiendid: Raske neerukahjustus (glomerulaarfiltratsiooni kiirus < 30 ml/min) ei mõjutanud oluliselt mikafungiini farmakokineetikat.
Patients with renal impairment: Severe renal impairment (Glomerular Filtration Rate [GFR] < 30 ml/min) did not significantly affect the pharmacokinetics of micafungin.
Neexistují žádné důkazy vlivu etnické příslušnosti na farmakokinetiku přípravku Intuniv.
There is no evidence of any impact of ethnicity on the pharmacokinetics of Intuniv.
Nefrolitiáza
Nephrolithiasis
Nefrotoxicitet
Nephrotoxicity
Nehematološka merila
Non-haematologic
Nehematološki
Non-haematological
Neisseria meningitidis OMPC (външно-мембранен протеинов комплекс 125 µg от щам B11 на Neisseria meningitidis subgroup B)
Neisseria meningitidis OMPC (outer membrane protein complex 125 µg of the B11 strain of Neisseria meningitidis subgroup B)
Nejlepšími způsoby, jak zvládnout tyto účinky, jsou včasná diagnóza a okamžité přerušení léčby kterýmkoliv podezřelým přípravkem.
The best results in managing these events come from early diagnosis and immediate interruption of any suspect medicines.
Nejsou k dispozici žádná farmakokinetická data získaná od pacientů s renální insuficiencí, kteří užívali atazanavir v kombinaci s kobicistatem.
There are no pharmacokinetic data available for atazanavir in combination with cobicistat in patients with renal insufficiency.
Nejsou k dispozici žádné klinické údaje o účincích orlistatu podávaného v době těhotenství.
For orlistat, no clinical data on exposed pregnancies are available.
Nejsou k dispozici žádné klinické údaje týkající se kobicistatu u těhotných žen nebo jsou tyto údaje omezené.
There are no or limited clinical data with cobicistat in pregnant women.
Nejčastěji hlášenou laboratorní abnormalitou u dětských pacientů užívajících atazanavir bylo zvýšení celkového bilirubinu ( ≥ 2,6násobek horní hranice normy, stupně 3-4), které se vyskytlo u 45 % pacientů.
The most frequently reported laboratory abnormality in paediatric patients receiving atazanavir was elevation of total bilirubin (≥ 2.6 times ULN, Grade 3-4) which occurred in 45% of patients.
Nekateri bolniki lahko po prvi podkožni injekciji 90 mg zdravila Stelara prejmejo na vsakih 8 tednov.
In some patients, after the first injection under the skin, 90 mg Stelara may be given every 8 weeks.
Nekateri dokazi kažejo, da statini kot razred zdravil povišajo raven glukoze in lahko pri nekaterih bolnikih z velikim tveganjem za razvoj sladkorne bolezni ustvarijo hiperglikemijo, ki zahteva uradno oskrbo sladkorne bolezni.
Some evidence suggests that statins as a class raise blood glucose and in some patients, at high risk of future diabetes, may produce a level of hyperglycaemia where formal diabetes care is appropriate.
Neklinické údaje získané na základě konvenčních farmakologických studií toxicity po opakovaném podávání, genotoxicity a reprodukční a vývojové toxicity neodhalily žádné zvláštní riziko pro člověka.
Non-clinical data reveal no special hazard for humans based on conventional studies of repeated dose toxicity, genotoxicity, and toxicity to reproduction and development.
Neklinične študije so pokazale, da zdravilo Teysuno ni vplivalo na plodnost samcev ali samic pri podganah (glejte poglavje 5.3).
Non- clinical studies demonstrated that Teysuno did not appear to affect male or female fertility in the rat (see section 5.3).
Neklinične študije so pokazale, da zdravilo Teysuno ni vplivalo na plodnost samcev ali samic pri podganah (glejte poglavje 5.3).
Non-clinical studies demonstrated that Teysuno did not appear to affect male or female fertility in the rat (see section 5.3).
Neklinični podatki na osnovi študij toksičnosti pri ponavljajočih odmerkih in vpliva na razvoj in sposobnost razmnoževanja, vključno s študijami za ovrednotenje farmakološke varnosti zdravila, ne kažejo nobenega posebnega tveganja za človeka (npr. glede toksičnosti za organe).
Non-clinical data reveal no special hazard (e.g. organ toxicity) for humans based on studies of repeated-dose toxicity and developmental and reproductive toxicity, including safety pharmacology evaluations.
Neklinični podatki na osnovi študij toksičnosti pri ponavljajočih odmerkih in vpliva na razvoj in sposobnost razmnoževanja, vključno s študijami za ovrednotenje farmakološke varnosti zdravila, ne kažejo posebnega tveganja za človeka (npr. glede toksičnosti za organe).
Non-clinical data reveal no special hazard (e.g. organ toxicity) for humans based on studies of repeated-dose toxicity and developmental and reproductive toxicity, including safety pharmacology evaluations.
Nekorigirano razmerje tveganja med skupino s peroralnim topotekanom in NPO ter skupino s samo NPO je bilo 0,64 (95 % IZ: 0,45, 0,90).
The unadjusted hazard ratio for oral topotecan plus BSC group relative to BSC alone group was 0.64 (95 % CI: 0.45, 0.90).
nekrolys
necrolysis
Nekrotična reakcija in z njo povezana vnetna reakcija nastajata več dni.
The necrotic reaction and associated inflammatory response evolve over several days.
NEL = без данни за левкемия/отговор на костния мозък
NEL = no evidence of leukaemia/marrow response
NEL: някои от критериите са както за CHR, но ANC ≥ 500/mm3 и < 1 000/mm3 и/или тромбоцити
NEL: same criteria as for CHR but ANC ≥ 500/mm3 and < 1,000/mm3, or platelets ≥ 20,000/mm3 and
NEL: същите критерии като за CHR, но ANC ≥ 500/mm3 и < 1 000/mm3, или тромбоцити ≥ 20 000/mm3 и
NEL: same criteria as for CHR but ANC ≥ 500/mm3 and < 1,000/mm3, or platelets ≥ 20,000/mm3 and
NELб
NELb
Nemdatine 10 mg таблетки мемантинов хидрохлорид
Nemdatine 10 mg tablets memantine hydrochloride
Nemdatine 10 mg тебалетки мемантинов хидрохлорид
Nemdatine 10 mg tablets memantine hydrochloride
Nemdatine 10 mg филмирани таблетки (таблетки) са бели, с форма на капсула, двойноизпъкнали, размер 9,8 mm x 4,9 mm, с делителна черта и надпис „M 10”, гравиран от страната на делителната черта.
Nemdatine 10 mg film-coated tablets (tablets) are white, capsule-shaped, biconvex, 9.8 mm x 4.9 mm in size, with score line and the marking “M 10” engraved on the scored side
Nemdatine 10 mg филмирани таблетки (таблетки) са бели, с форма на капсула, двойноизпъкнали, размер 9,8 mm x 4,9 mm, с делителна черта и надпис „M 10”, гравиран от страната с делителна черта.
Nemdatine 10 mg film-coated tablets (tablets) are white, capsule-shaped, biconvex, 9.8 mm x 4.9 mm in size, with score line and the marking “M 10” engraved on the scored side.
Nemdatine 10 mg филмирани таблетки мемантинов хидролорид
Nemdatine 10 mg film-coated tablets memantine hydrochloride
Nemdatine 10 mg филмирани таблетки мемантинов хидрохлорид
Nemdatine 10 mg film-coated tablets memantine hydrochloride
Nemdatine 15 mg таблетки мемантинов хидролорид
Nemdatine 15 mg tablets memantine hydrochloride
Nemdatine 15 mg таблетки мемантинов хидрохлорид
Nemdatine 15 mg tablets memantine hydrochloride
Nemdatine 15 mg филмирани таблетки мемантинов хидрихлорид
Nemdatine 15 mg film-coated tablets memantine hydrochloride
Nemdatine 20 mg таблетки мемантинов хидролорид
Nemdatine 20 mg tablets memantine hydrochloride
Nemdatine 20 mg таблетки мемантинов хидрохлорид
Nemdatine 20 mg tablets memantine hydrochloride
Nemdatine 20 mg филмирани таблетки мемантинов хидрохлорид
Nemdatine 20 mg film-coated tablets memantine hydrochloride
Nemdatine 5 mg таблетки мемантинов хидролорид
Nemdatine 5 mg tablets memantine hydrochloride
Nemdatine 5 mg таблетки мемантинов хидрохлорид
Nemdatine 5 mg tablets memantine hydrochloride
Nemdatine 5 mg филмирани таблетки Nemdatine 10 mg филмирани таблетки Nemdatine 15 mg филмирани таблетки Nemdatine 20 mg филмирани таблетки мемантинов хидрохлорид (memantine hydrochloride)
Nemdatine 5 mg film-coated tablets Nemdatine 10 mg film-coated tablets Nemdatine 15 mg film-coated tablets Nemdatine 20 mg film-coated tablets Memantine hydrochloride
Nemdatine 5 филмирани таблетки мемантинов хидролорид
Nemdatine 5 mg film-coated tablets memantine hydrochloride
Nemdatine е лекарство, което се използва за лечение на пациенти с умерено до тежко изразена болест на Алцхаймер, вид деменция (мозъчно нарушение), която постепенно засяга паметта, интелектуалните способности и поведението.
Nemdatine is a medicine used to treat patients with moderate to severe Alzheimer’s disease, a type of dementia (a brain disorder) that gradually affects memory, intellectual ability and behaviour.
Nemdatine е „генерично лекарство“.
Nemdatine is a ‘generic medicine’.
Nemdatine не се препоръчва за употреба при деца и юноши на възраст под 18 години.
Nemdatine is not recommended for children and adolescents under the age of 18 years.
Nemdatine с храни и напитки
Nemdatine with food and drink
Nemdatine се използва за лечение на пациенти с умерено до тежко изразена болест на Алцхаймер.
Nemdatine is used for the treatment of patients with moderate to severe Alzheimer’s disease.
Nemdatine се отнася към група лекарства, наречени NMDA-рецепторни антагонисти .
Nemdatine belongs to a group of medicines called NMDA- receptor antagonists.
Nemdatine се отнася към група лекарства, наречени NMDA-рецепторни антагонисти.
Nemdatine belongs to a group of medicines called NMDA- receptor antagonists.
Nemdatine трябва да се прилага веднъж дневно и да се приема по едно и също време всеки ден.
Nemdatine should be administered once a day and should be taken at the same time every day.
Nemdatine трябва да се прилага веднъж дневно, да се приема по едно и също време всеки ден.
Nemdatine should be administered once a day and should be taken at the same time every day.
Nemdatine трябва да се прилага през устата веднъж дневно.
Nemdatine should be administered orally once a day.
nemir,
Restlessness
Nemohou být vydána žádná doporučení týkající se užívání přípravku EVOTAZ s perorální antikoncepcí (viz bod 4.5).
No dosing recommendations can be made regarding the use of EVOTAZ with oral contraceptives (see section 4.5).
Nemudoma obvestite svojega zdravnika: če opazite spremembe vida.
Tell your doctor immediately: if you notice a change in your eyesight.
nemudoma vprašajte za nasvet svojega zdravnika ali v najbližjo bolnišnico, boste morda izkusili bruhanje, nemir ali katerega od neželenih učinkov, opisanih v poglavju 4 (Možni neželeni učinki).
You may experience vomiting, restlessness, or any of the side effects as described in chapter 4 “Possible side effects”.
Nenadna hladnost z omedlevico, šibkostjo ali kolapsom.
Sudden coldness with fainting, limpness or collapse.
Nenadna prekinitev lahko povzroči razvoj bolezenskega stanja, imenovanega nevroleptični maligni sindrom, ki lahko predstavlja večjo nevarnost za zdravje.
A sudden stop could cause you to develop a medical condition called neuroleptic malignant syndrome which may represent a major health risk.
Nenadno otekanje kože in sluznic (npr. grla ali jezika) zaradi kopičenja tekočine (angioedem)
Sudden swelling of the skin and mucosa (e.g. throat or tongue) caused by fluid build up (angioedema).
Nenamerna izpostavitev bolnišničnega osebja zdravilu INOmax je bila povezana z neželenimi dogodki (glejte poglavje 4.8).
Accidental exposure to INOmax in hospital staff has been associated with adverse events (see section 4.8).
Nenamerna izpostavljenost zdravilu
Accidental exposure
Nende metaboliitide ekspositsioon on madal ja metaboliidid ei osale mikafungiini üldises toimes.
Exposure to these metabolites is low and metabolites do not contribute to the overall efficacy of micafungin.
Nende uuringute käigus ei täheldatud muutusi mikafungiini farmakokineetikas.
No micafungin dose adjustments are necessary when these medicines are administered concomitantly.
Nendes mudelites oli C. albicans´i ja C. glabrata nõutav suhe vastavalt ~2400 ja ~1300.
A ratio of ~2400 and ~1300 was required for C. albicans and C. glabrata, respectively, in these models.
nenormalen srčni utrip
abnormal heart rate
nenormalna frekvenca srca ali premajhen dotok krvi v srce
abnormal heart rate or lack of blood flow to the heart
nenormalne sanje,
Abnormal dreams
nenormalne sanje,
Constipation
nenormalno visoka ali nizka koncentracija kalija v krvi
abnormally high or low levels of potassium in the blood
Není možné vyloučit potenciální lékové interakce s léky, které inhibují OCT1.
Potential drug interactions with drugs that inhibit OCT1 cannot be excluded.
Není pravděpodobné, že by léčebné použití orlistatu představovalo riziko pro vodní a suchozemské životní prostředí.
Nonclinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, and toxicity to fertility, reproduction and development.
Není pravděpodobné, že klopidogrel ovlivňuje schopnost řídit motorová vozidla nebo obsluhovat stroje.
Clopidogrel BMS is unlikely to affect your ability to drive or to use machines.
Není známo, jak často se tyto nežádoucí účinky vyskytují
It is not known how frequently these side effects occur
Není známo, jak často se tyto účinky vyskytují
It is not known how frequently these effects occur
Není známo, zda má přípravek Intuniv vliv na nenarozené dítě.
It is not known if Intuniv will affect your unborn baby.